Unfortunately, this website doesn't work in your browser.
The browser you are using is no longer supported by Microsoft—we highly recommend upgrading as soon as possible.

Veincentre Investment from Santander

February 2020 Not Disclosed

Back to Deals

growth strategy

Project Channel

February 2020 Not Disclosed

About the client

Veincentre is an excellent business that is meeting an unmet need in healthcare.

Veincentre delivers specialist treatment for varicose veins, using Endovenous Laser Ablation (EVLA). Utilising EVLA – a non-invasive, non-surgical procedure – Veincentre can reduce the surgical and recovery times associated with traditional forms of treatment, meaning patients can often have their veins treated in their lunch-hour. EVLA also significantly reduces scarring, limiting the damage done by the condition.

Following the withdrawal of NHS funding for varicose vein sufferers – due to their ‘non-essential’ status – Veincentre is well-placed to offer affordable, accessible treatment to patients across its seven UK-wide clinics.

About the deal

Rickitt Mitchell has successfully advised Veincentre on a refinance process which has resulted in significant funds being received from Santander. This follows investment from Manchester-based Palatine Private Equity in July 2019.

Veincentre, a provider of treatment for varicose veins, plans to utilise the funds to facilitate the expansion of additional clinics, as it looks to launch a Liverpool site in the first quarter of 2020 and a further two new clinics before the end of the year.

The Company will also invest further in digital transformation with the development of a new website and digital marketing strategy.

Veincentre was advised by Neil Mitchell and Kaine Smith at Rickitt Mitchell.

“Veincentre is a fantastic business with ambitious plans to expand its affordable service provision across the UK. We look forward to supporting the company with its growth strategy over the coming years.”

Kaine Smith | Rickitt Mitchell